Cargando…

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol

BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β(2)-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic...

Descripción completa

Detalles Bibliográficos
Autores principales: Calverley, Peter MA, Martinez, Fernando J, Fabbri, Leonardo M, Goehring, Udo-Michael, Rabe, Klaus F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393336/
https://www.ncbi.nlm.nih.gov/pubmed/22791991
http://dx.doi.org/10.2147/COPD.S31100
_version_ 1782237725835919360
author Calverley, Peter MA
Martinez, Fernando J
Fabbri, Leonardo M
Goehring, Udo-Michael
Rabe, Klaus F
author_facet Calverley, Peter MA
Martinez, Fernando J
Fabbri, Leonardo M
Goehring, Udo-Michael
Rabe, Klaus F
author_sort Calverley, Peter MA
collection PubMed
description BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β(2)-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic [long-acting muscarinic antagonist]). Roflumilast is approved to treat severe COPD in patients with chronic bronchitis – and a history of frequent exacerbations – as an add-on to bronchodilators. PURPOSE: The REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment) study (identification number RO-2455-404-RD, clinicaltrials. gov identifier NCT01329029) will investigate whether roflumilast further reduces exacerbations when added to inhaled combination therapy in patients still suffering from frequent exacerbations. PATIENTS AND METHODS: REACT is a 1-year randomized, double-blind, multicenter, phase III/IV study of roflumilast 500 μg once daily or placebo on top of a fixed long-acting β(2)-agonist/inhaled corticosteroid combination. A concomitant long-acting muscarinic antagonist will be allowed at stable doses. The primary outcome is the rate of moderate or severe COPD exacerbations. Using a Poisson regression model with a two-sided significance level of 5%, a sample size of 967 patients per treatment group is needed for 90% power. COPD patients with severe to very severe airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previous year will be recruited. CONCLUSION: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators. REACT will be important to determine the role of roflumilast in COPD management. Here, the design and rationale for this important study is described.
format Online
Article
Text
id pubmed-3393336
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33933362012-07-12 Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol Calverley, Peter MA Martinez, Fernando J Fabbri, Leonardo M Goehring, Udo-Michael Rabe, Klaus F Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β(2)-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic [long-acting muscarinic antagonist]). Roflumilast is approved to treat severe COPD in patients with chronic bronchitis – and a history of frequent exacerbations – as an add-on to bronchodilators. PURPOSE: The REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment) study (identification number RO-2455-404-RD, clinicaltrials. gov identifier NCT01329029) will investigate whether roflumilast further reduces exacerbations when added to inhaled combination therapy in patients still suffering from frequent exacerbations. PATIENTS AND METHODS: REACT is a 1-year randomized, double-blind, multicenter, phase III/IV study of roflumilast 500 μg once daily or placebo on top of a fixed long-acting β(2)-agonist/inhaled corticosteroid combination. A concomitant long-acting muscarinic antagonist will be allowed at stable doses. The primary outcome is the rate of moderate or severe COPD exacerbations. Using a Poisson regression model with a two-sided significance level of 5%, a sample size of 967 patients per treatment group is needed for 90% power. COPD patients with severe to very severe airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previous year will be recruited. CONCLUSION: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators. REACT will be important to determine the role of roflumilast in COPD management. Here, the design and rationale for this important study is described. Dove Medical Press 2012 2012-06-20 /pmc/articles/PMC3393336/ /pubmed/22791991 http://dx.doi.org/10.2147/COPD.S31100 Text en © 2012 Calverley et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Calverley, Peter MA
Martinez, Fernando J
Fabbri, Leonardo M
Goehring, Udo-Michael
Rabe, Klaus F
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
title Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
title_full Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
title_fullStr Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
title_full_unstemmed Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
title_short Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
title_sort does roflumilast decrease exacerbations in severe copd patients not controlled by inhaled combination therapy? the react study protocol
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393336/
https://www.ncbi.nlm.nih.gov/pubmed/22791991
http://dx.doi.org/10.2147/COPD.S31100
work_keys_str_mv AT calverleypeterma doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol
AT martinezfernandoj doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol
AT fabbrileonardom doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol
AT goehringudomichael doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol
AT rabeklausf doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol